JP2021534239A - Ｒｓｖの改善された受動的および能動的ワクチン - Google Patents

Ｒｓｖの改善された受動的および能動的ワクチン Download PDF

Info

Publication number
JP2021534239A
JP2021534239A JP2021531465A JP2021531465A JP2021534239A JP 2021534239 A JP2021534239 A JP 2021534239A JP 2021531465 A JP2021531465 A JP 2021531465A JP 2021531465 A JP2021531465 A JP 2021531465A JP 2021534239 A JP2021534239 A JP 2021534239A
Authority
JP
Japan
Prior art keywords
seq
rsv
protein
mab
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534239A5 (https=
Inventor
フリードマン，ミルトン・ジェイ
カウヴァル，ローレンス・エム
Original Assignee
トレリス・バイオサイエンス，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トレリス・バイオサイエンス，エルエルシー filed Critical トレリス・バイオサイエンス，エルエルシー
Publication of JP2021534239A publication Critical patent/JP2021534239A/ja
Publication of JP2021534239A5 publication Critical patent/JP2021534239A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021531465A 2018-08-08 2019-08-08 Ｒｓｖの改善された受動的および能動的ワクチン Pending JP2021534239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716184P 2018-08-08 2018-08-08
US62/716,184 2018-08-08
PCT/US2019/045775 WO2020033742A1 (en) 2018-08-08 2019-08-08 Improved rsv passive and active vaccines

Publications (2)

Publication Number Publication Date
JP2021534239A true JP2021534239A (ja) 2021-12-09
JP2021534239A5 JP2021534239A5 (https=) 2022-08-17

Family

ID=69415133

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531465A Pending JP2021534239A (ja) 2018-08-08 2019-08-08 Ｒｓｖの改善された受動的および能動的ワクチン

Country Status (5)

Country Link
US (2) US12246063B2 (https=)
EP (1) EP3833677A4 (https=)
JP (1) JP2021534239A (https=)
CA (1) CA3107037A1 (https=)
WO (1) WO2020033742A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5589231A (en) * 1978-12-15 1980-07-05 Sandoz Ag Vaccine
JP2011500091A (ja) * 2007-10-25 2011-01-06 トレリス バイオサイエンス、インク． 抗ｒｓｖｇタンパク質抗体
WO2017075124A1 (en) * 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0777685B1 (en) * 1994-08-25 1999-04-14 Stichting Instituut voor Dierhouderij en Diergezondheid Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
CA2426312C (en) 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
MX387277B (es) 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
WO2017132550A1 (en) 2016-01-28 2017-08-03 The Brigham And Women's Hospital, Inc. Detection of an antibody against a pathogen
CA3079604A1 (en) 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
US20200033307A1 (en) 2018-07-25 2020-01-30 Honeywell International Inc. Method of determining an amount of water in a sample using a derivative of imidazole and a hydrogen halide donor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5589231A (en) * 1978-12-15 1980-07-05 Sandoz Ag Vaccine
JP2011500091A (ja) * 2007-10-25 2011-01-06 トレリス バイオサイエンス、インク． 抗ｒｓｖｇタンパク質抗体
WO2017075124A1 (en) * 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRADY, L. JEANNINE, INFECTION AND IMMUNITY, vol. 73, no. 2, JPN6023032786, February 2005 (2005-02-01), pages 671 - 678, ISSN: 0005307099 *
FEDECHKIN, STANISLAV O. ET AL., SCIENCE IMMUNOLOGY, vol. Vol. 3, No. 21, Article No. eaar3534, JPN6023032785, 9 March 2018 (2018-03-09), ISSN: 0005307098 *
KRUIJSEN, DEBBY ET AL., JOURNAL OF VIROLOGY, vol. 87, no. 13, JPN6023032787, July 2013 (2013-07-01), pages 7550 - 7557, ISSN: 0005307100 *
ROBBIE, GABRIEL J. ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 57, no. 12, JPN6023032784, December 2013 (2013-12-01), pages 6147 - 6153, ISSN: 0005307097 *

Also Published As

Publication number Publication date
EP3833677A1 (en) 2021-06-16
EP3833677A4 (en) 2022-04-27
CA3107037A1 (en) 2020-02-13
WO2020033742A1 (en) 2020-02-13
US12246063B2 (en) 2025-03-11
US20250195636A1 (en) 2025-06-19
US20210268096A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP6328061B2 (ja) Ｂ型インフルエンザウイルスに結合して中和することができるヒト結合分子およびその使用
CN107667115B (zh) 针对埃博拉病毒糖蛋白的人抗体
CN114716541B (zh) 抗冠状病毒的全人广谱中和抗体76e1及其应用
US11723977B2 (en) Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
SA96170384B1 (ar) وطرق تحضيرها واستخداماتها العلاجية (rsv) الاجسام المضادة المعادلة البشرية احادية النسيلة ذات الالفة العالية المختصة ببروتين - ف للفيروس المخلوي التنفسي
JP2019528050A (ja) 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法
CA3202566A1 (en) Neutralizing monoclonal antibodies against covid-19
TW202221024A (zh) 結合sars-cov-2 s蛋白之中和抗體
US20230212231A1 (en) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
KR20200115517A (ko) 인플루엔자 헤마글루티닌에 대한 인간 항체
WO2020143799A1 (zh) 广谱性中和流感病毒的全人抗体
CN108794624A (zh) 抗h7n9流感病毒的中和性单克隆抗体
JP2020536934A (ja) 呼吸器合胞体ウイルスｇタンパク質中央保存領域の立体構造エピトープ
US20170198061A1 (en) Influenza vaccines and methods of use thereof
US12246063B2 (en) Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
CN110343172B (zh) 一种高灵敏度的黄热病毒人源单克隆抗体及其应用
US20240285753A1 (en) Epitope-scaffold immunogens for pancoronavirus vaccines
Muhammed et al. Breakthroughs in SARS-CoV-2-monoclonal antibodies development
KR20260047586A (ko) 인플루엔자 b 바이러스에 대한 광범위 반응성 항체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240418